BioNTech SE (NASDAQ:BNTX) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its position in BioNTech SE (NASDAQ:BNTX) by 18.8% in the fourth quarter, HoldingsChannel reports. The fund owned 110,790 shares of the company’s stock after selling 25,594 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in BioNTech were worth $117,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of BNTX. Truist Financial Corp purchased a new position in shares of BioNTech in the 4th quarter valued at about $1,445,000. Fifth Third Bancorp grew its holdings in BioNTech by 3,881.3% in the fourth quarter. Fifth Third Bancorp now owns 16,642 shares of the company’s stock valued at $1,756,000 after purchasing an additional 16,224 shares during the period. Bamco Inc. NY increased its position in shares of BioNTech by 123.1% in the third quarter. Bamco Inc. NY now owns 158,911 shares of the company’s stock valued at $17,264,000 after buying an additional 87,686 shares in the last quarter. Kestra Private Wealth Services LLC acquired a new position in shares of BioNTech during the 4th quarter worth approximately $938,000. Finally, abrdn plc purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $10,961,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BNTX shares. Evercore ISI started coverage on shares of BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target for the company. BMO Capital Markets reduced their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. UBS Group decreased their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. TD Cowen boosted their price objective on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Finally, The Goldman Sachs Group decreased their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $111.70.

BioNTech Stock Performance

BioNTech stock opened at $96.95 on Friday. The firm has a 50 day simple moving average of $90.92 and a 200-day simple moving average of $95.84. The stock has a market cap of $23.05 billion, a price-to-earnings ratio of 193.90 and a beta of 0.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. BioNTech SE has a 1-year low of $85.21 and a 1-year high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. On average, analysts expect that BioNTech SE will post -2.11 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.